Bedaquiline is an antibiotic used primarily to treat drug-resistant tuberculosis, the forms of TB that no longer respond to the standard first-line drugs like rifampicin and isoniazid. It was the first new class of TB drug approved in roughly four decades, and it works by a mechanism unlike any other antibiotic on the market: shutting down the energy-producing machinery of the TB bacterium. Since its accelerated approval in 2012, bedaquiline has moved from a last-resort add-on to the backbone of the World Health Organization’s recommended regimens for multidrug-resistant TB.
How Bedaquiline Kills TB Bacteria
Most antibiotics attack bacteria by disrupting their cell walls, blocking protein production, or interfering with DNA replication. Bedaquiline does something different. It targets an enzyme called ATP synthase, which is the molecular turbine that TB bacteria use to generate ATP, the molecule that fuels virtually every cellular process. Specifically, bedaquiline binds to the rotating part of that enzyme, called the c-ring, and physically blocks the sites where ions normally pass through. Without ion flow, the rotor stalls and the bacterium can no longer produce the energy it needs to survive.1PubMed Central. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline
The original discovery paper, published in Science in 2005, identified the compound (then called R207910) as potent against both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis in laboratory tests, with very low concentrations needed to stop the bacteria from growing.2PubMed. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis This mechanism matters practically because it means bedaquiline retains its potency against TB strains that have already developed resistance to conventional antibiotics. The mutations that make bacteria resistant to rifampicin or isoniazid do not affect ATP synthase, so bedaquiline arrives at the fight through a completely separate door.
One quirk of this mechanism is that the killing effect is not immediate. Because bedaquiline blocks energy production rather than directly damaging a structural component, the bacterium does not die until its existing ATP reserves run out. This delayed bactericidal activity means the drug’s full killing power takes days to ramp up, but once it does, it matches the potency of frontline drugs like isoniazid and rifampicin.3PubMed Central. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
What Bedaquiline Is Used For
Bedaquiline’s primary role is treating multidrug-resistant TB (MDR-TB), meaning TB that resists at least rifampicin and isoniazid, and extensively drug-resistant TB (XDR-TB), which adds resistance to fluoroquinolones and other second-line drugs. Before bedaquiline, treatment for these forms of TB relied on older, less effective drugs often given by injection, with courses lasting up to two years and cure rates that were discouragingly low. A U.S. cohort study found that bedaquiline-containing regimens showed favorable safety, culture conversion, and treatment completion rates in patients with MDR and XDR-TB.4PubMed Central. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States
The bigger shift came when bedaquiline was placed at the center of shorter, all-oral regimens. In 2020, the WHO recommended replacing painful injectable agents with bedaquiline in shorter treatment courses for patients whose TB is not also resistant to fluoroquinolones, making the regimen entirely oral and cutting treatment from as long as 20 months down to 9 to 11 months.5European Respiratory Journal. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update This was a substantial quality-of-life improvement for patients. Injectable drugs like kanamycin and capreomycin caused hearing loss and kidney damage, and required daily clinic visits for injections.
The BPaLM Regimen
The most significant recent development is a six-month regimen known as BPaLM: bedaquiline, pretomanid, linezolid, and moxifloxacin. The WHO prioritized this combination in its 2022 update as the preferred treatment for rifampicin-resistant and multidrug-resistant TB. Each drug in the combination hits the bacterium through a different mechanism, which improves killing and reduces the chance of resistance emerging during treatment.
A systematic review found that the BPaLM regimen, compared with older standard-of-care approaches, reduced the risk of poor outcomes, with roughly one in seven patients avoiding an unfavorable result who otherwise would have had one. It also reduced treatment dropouts and serious side effects compared with longer regimens.6PubMed Central. Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review Real-world data from Belarus and Uzbekistan reinforced those findings: in a cohort of nearly 700 patients treated with BPaL-based regimens outside clinical trial settings, about 94% had a successful treatment outcome, with cure rates above 83% even in patients with pre-XDR-TB.7Clinical Infectious Diseases. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings
For a disease that historically had treatment success rates below 60% in its most resistant forms, those numbers represent a dramatic improvement. The fact that the regimen takes six months rather than 18 to 24 also matters enormously for patients in low-resource settings, where staying on treatment for nearly two years is a logistical and financial burden that many cannot sustain.
QTc Prolongation and Heart Rhythm Concerns
The side effect that gets the most attention with bedaquiline is QTc prolongation, a measurable change in the heart’s electrical activity that, in extreme cases, can lead to dangerous arrhythmias. Bedaquiline and its active metabolite (called M2) interfere with certain potassium channels in heart cells, which delays the heart’s electrical recovery between beats. In a randomized controlled trial, bedaquiline increased the QTc interval by an average of about 12 milliseconds from baseline. When combined with delamanid, another newer TB drug, the effect was roughly additive, at about 21 milliseconds, but no patients experienced clinically dangerous prolongation events, and no deaths occurred during the study.8PubMed Central. QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN PATIENTS WITH RIFAMPICIN-RESISTANT-TB: A RANDOMIZED CONTROLLED TRIAL
Pharmacokinetic modeling has found that the M2 metabolite, not the parent drug, is primarily responsible for the QTc effect. Reassuringly, simulations suggest that even at the higher end of observed drug exposure levels, critical QTc increases are not expected.9PubMed Central. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis In clinical practice, patients on bedaquiline are monitored with periodic electrocardiograms, and clinicians watch for other medications in the regimen that might compound the effect. The QTc concern is real but manageable, and it has not proven to be the barrier many feared when the drug was first introduced.
The Black Box Warning and the Mortality Question
When bedaquiline received accelerated approval in 2012, it came with a black box warning, the most serious type of safety alert the FDA applies. This was based on an unexpected finding from the pivotal phase 2b trial: more deaths occurred in the bedaquiline arm than in the placebo arm. The warning unsettled clinicians and slowed uptake for years, even as it became clear that the deaths were not straightforwardly caused by the drug. Nearly all of the deaths occurred after bedaquiline had been stopped, and the causes were varied.10Taylor & Francis Online (Expert Opinion on Drug Safety). A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis
The mortality imbalance haunted the drug’s reputation for years, but subsequent larger studies and real-world data have not confirmed a survival disadvantage. The WHO and other guideline bodies have since placed bedaquiline at the center of recommended regimens, a decision that would not have been made if the drug carried a true mortality risk exceeding its benefit. The episode is worth understanding because it illustrates a broader tension in TB drug development: the patients who receive new TB drugs are among the sickest, often with strains resistant to everything else, and attributing deaths in that population to any single drug is genuinely difficult.
Liver Effects
Beyond the heart, the liver is the other organ clinicians watch closely. A nationwide retrospective study found that bedaquiline-containing regimens were associated with a higher risk of acute liver injury, though the authors cautioned that other TB drugs in the same regimen, several of which are well-known liver toxins, make it hard to pin the blame on bedaquiline alone.11PubMed. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study A systematic review and meta-analysis looking at liver enzyme elevations found that bedaquiline-only regimens had rates of elevated liver enzymes similar to standard-of-care regimens, while combinations of bedaquiline with pretomanid tended to push those rates higher.12PubMed. Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis The practical takeaway is that liver function tests are part of routine monitoring during treatment, and clinicians adjust or pause therapy if enzymes rise significantly.
Why It Stays in the Body for Months
Bedaquiline is an unusually lipophilic (fat-loving) molecule. It is virtually insoluble in water and instead accumulates extensively in fatty tissues throughout the body. Its volume of distribution is large, more than 99% of the drug binds to proteins in the blood, and its terminal elimination half-life is around four to five months.13ACS Infectious Diseases. Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects This means the drug lingers in the body long after a patient stops taking it, which has both advantages and drawbacks. On the plus side, it sustains drug levels at the site of infection for extended periods. On the minus side, any side effects (like the QTc prolongation discussed earlier) can persist well beyond the last dose.
Food intake significantly affects how much of the drug gets absorbed. Taking bedaquiline with a high-fat meal can roughly double both peak blood levels and total exposure compared to taking it on an empty stomach.13ACS Infectious Diseases. Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects This is why patients are advised to take the drug with food, and why adherence counseling includes instructions about mealtime dosing.
Drug Interactions with HIV Medications
Because drug-resistant TB and HIV frequently overlap, especially in sub-Saharan Africa, the interaction between bedaquiline and antiretroviral drugs is a major practical concern. Bedaquiline and its M2 metabolite are broken down in the liver by the enzyme CYP3A4. Some HIV drugs powerfully inhibit that enzyme, which can cause bedaquiline to build up to much higher levels than intended.
The most important interaction is with lopinavir/ritonavir, an older protease inhibitor combination. In patients taking both, bedaquiline exposure roughly doubled compared with patients not on antiretrovirals, and its half-life increased substantially.14PubMed. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB Population pharmacokinetic modeling confirmed this: lopinavir/ritonavir reduced bedaquiline’s clearance to roughly a quarter of its normal value.15PubMed. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis By contrast, nevirapine, which mildly induces CYP3A4, did not produce a clinically meaningful interaction. In practice, this means HIV treatment regimens often need to be adjusted when a patient starts bedaquiline, favoring antiretrovirals like efavirenz or dolutegravir that interact less with the CYP3A4 pathway.
Bedaquiline in Children
For years, children with drug-resistant TB had almost no evidence-based treatment options, because new TB drugs were tested only in adults. Bedaquiline is gradually changing that. A phase 2 trial in children and adolescents aged 5 to 17 found that appropriate weight-based dosing achieved drug exposure levels comparable to those seen in adults, with a similarly reassuring safety profile: no dangerous QTc prolongation, few serious adverse events, and no deaths during the study.16PubMed Central. Bedaquiline for multidrug-resistant TB in paediatric patients
Modeling work for once-daily dosing in children has been encouraging as well, suggesting that even though children have relatively higher systemic drug exposure, the levels of the M2 metabolite (the main driver of QTc prolongation) stay within safe limits in the vast majority of cases.17PubMed Central. Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis A practical hurdle for younger children is that bedaquiline is only available as tablets, not a liquid. Researchers have shown that stable suspensions can be prepared from crushed tablets mixed in simple syrup or a sugar-free vehicle, maintaining potency for 15 to 30 days at room temperature, which makes field dosing more feasible.18PubMed Central. Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field
How Resistance to Bedaquiline Develops
Given how central bedaquiline has become, resistance is a growing worry. Researchers have identified three genes where mutations can reduce the drug’s effectiveness. The most common route is through mutations in a gene called Rv0678, which controls an efflux pump: a molecular sump pump that bacteria use to flush the drug out of their cells before it can reach its target. A second, less common but more potent route involves mutations in the atpE gene, which encodes the very part of ATP synthase that bedaquiline binds to, altering the target so the drug no longer fits. A third gene, pepQ, has also been implicated.19Clinical Infectious Diseases. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention
In laboratory experiments, Rv0678 mutations tend to appear first, providing low-level resistance, while atpE mutations arise later under continued drug pressure and confer higher-level resistance.20PubMed Central. In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance In one study, over 90% of resistant isolates carried only Rv0678 mutations, while fewer than 5% of bedaquiline-selected isolates had atpE changes.21Scientific Reports. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678 The Rv0678 efflux pump pathway is especially concerning because it also reduces susceptibility to clofazimine, another key drug in TB treatment, meaning a single mutation can compromise two drugs at once.
Detecting Resistance Is Harder Than It Sounds
One of the challenges with bedaquiline resistance is that standard diagnostic tools struggle to catch it reliably. A large genomic meta-analysis found that even using the most sensitive possible genetic approach, where any mutation in any gene linked to bedaquiline resistance is assumed to be meaningful, only about half to two-thirds of phenotypic resistance could be identified.22The Lancet Microbe. Genomic epidemiology and predictive diagnostics of bedaquiline resistance in Mycobacterium tuberculosis: a systematic review and individual isolate meta-analysis That means a significant fraction of resistant strains would be missed by DNA-based tests.
Traditional culture-based drug susceptibility testing has its own blind spots. A recent study showed that a phenomenon called heteroresistance, where a minority of bacteria in a sample are resistant while the majority are still susceptible, can only be detected if laboratories pay attention to intermediate results that are routinely discarded. Including those intermediate readings caught heteroresistance at a rate of about 1%, which sounds small but could make a meaningful clinical difference if it allows earlier detection and treatment adjustment.23PubMed Central. Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing This is an area where the science is actively evolving, and better diagnostic tools would significantly improve how resistance is managed.
Activity Against Non-Tuberculous Mycobacteria
While bedaquiline was developed for TB, researchers have been exploring whether it works against non-tuberculous mycobacteria (NTM), a group of related organisms that cause increasingly common lung infections, particularly in people with underlying lung diseases or weakened immune systems. NTM infections are notoriously hard to treat, often requiring combinations of multiple antibiotics taken for a year or more.
A systematic review and meta-analysis found that bedaquiline showed strong antibacterial activity against various NTM species both in laboratory settings and in patients.24PubMed Central. Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis Lab testing in China showed especially promising activity against Mycobacterium avium, a common NTM pathogen, with very low drug concentrations needed to inhibit growth. Activity against Mycobacterium abscessus, another clinically important species, was more variable.25PubMed Central. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China Bedaquiline is not yet approved for NTM infections, but it is being used off-label in difficult-to-treat cases, and clinical trials are underway to build the evidence base.
Access, Patents, and the Cost of a Critical Drug
Bedaquiline’s global story cannot be told without addressing access. The drug was developed by Janssen Pharmaceutica and initially sold under the brand name Sirturo. For years, its high cost and limited supply meant that many of the patients who needed it most, in countries like India, South Africa, and the Philippines where drug-resistant TB is concentrated, could not get it. India’s decision to deny a patent extension for bedaquiline was one of the most prominent public health fights over the drug, framed as a clash between intellectual property protections and the urgent need for affordable generic production.26PubMed Central. India’s Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative
With the primary patent having expired, generic production is now expanding, and prices are dropping. This is critical because the WHO’s recommended BPaLM regimen cannot be scaled globally if one of its cornerstone drugs remains unaffordable. How quickly affordable bedaquiline reaches the patients who need it will likely determine how many lives the drug ultimately saves.